Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML



Status:Completed
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - 60
Updated:9/20/2018
Start Date:February 6, 2014
End Date:April 30, 2018

Use our guide to learn which trials are right for you!

A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia

To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy
reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem
cell transplant,


Inclusion Criteria:

- Patients must be between 18 and 60 years of age

- Patients must have an ECOG Performance Status of < 2

- Patients must have a documented Unequivocal diagnosis of AML according to WHO 2008
classification (>20% blasts in the bone marrow), excluding M3 (acute promyelocytic
leukemia).

- Patients must have a documented FLT3 ITD mutation, determined by local laboratory for
eligibility (historical tissue will be requested for central analysis confirmation)

- Patients who have undergone allogeneic HSCT in CR1 from a matched related or matched
unrelated donor. All of the following criteria must also be met:

HLA typing to include available 8/8 or 7/8 allele HLA matched donor (at A,B,C, DRB1) Single
allelic mismatch allowed • Patients who received a conditioning regimen which included one
of the following: Busulfan/Fludarabine (Bu/Flu) Busulfan (16 mg/kg PO or 12.8 mg/kg IV)
Fludarabine (120-180 mg/m2) Fludarabine / Melphalan (Flu/Mel) Fludarabine (120-180 mg/m2)
Melphalan (≤ 150 mg/m2) Busulfan/Cyclophosphamide (Bu/Cy) Busulfan (16 mg/kg PO or 12.8
mg/kg IV) Cyclophosphamide (120 mg/kg) Cyclophosphamide/Total Body Irradiation (Cy/TBI)
Cyclophosphamide (120 mg/kg) TBI (1200-1420 cGy)

• Recovery of counts by day 42 and able to start midostaurin by day 60 post-HSCT (first
dose of midostaurin to start no earlier than 28 days post-HSCT); ANC >1000µL, platelets
≥20,000 without platelet transfusion

Exclusion Criteria:

- Patients whom have failed prior attempts at allogeneic HSCT

- Patients who have received an autologous transplant

- Patients with Acute GVHD Grade III-IV

- Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.

- Impaired cardiac function including any of the following:

- Screening ECG with a QTc > 450 msec. If QTc > 450 and electrolytes are not within
normal ranges, electrolytes should be corrected and then the patient rescreened
for QTc.

- Patients with congenital long QT syndrome

- History or presence of sustained ventricular tachycardia

- Any history of ventricular fibrillation or torsades de pointes

- Bradycardia defined as HR. < 50 bpm

- Right bundle branch block + left anterior hemiblock (bifascicular block)

- Patients with myocardial infarction or unstable angina < 6 months prior to
starting study

- Congestive Heart Failure NY Heart Association class III or IV

- Patients with an ejection fraction < 45% assessed by MUGA or ---ECHO within 28
days prior to starting study cycle 1 (of midostaurin or control group)

- Patients with any pulmonary infiltrate including those suspected to be of infectious
origin (unless resolves to ≤ Grade 1 within screening timeframe)

- Patient requires treatment with strong CYP3A4 inhibitors or moderate or strong CYP3A4
inducers other than those required for GVH or infection prophylaxis or treatment

Pregnant or nursing (lactating) women, or women of child-bearing potential, must use highly
effective methods of contraception during dosing and for 30 days after treatment completion

Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
19
sites
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Mrinal R. Patnaik
Phone: 507-284-2467
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Kent Holland
Phone: 404-851-5926
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Thomas C. Shea
Phone: 919-966-7746
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
Principal Investigator: Wendy Stock
Phone: 773-834-2487
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44194
Principal Investigator: Brenda W. Cooper
Phone: 216-844-8447
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Edward B. Agura
Phone: 214-818-8471
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Peter McSweeney
Phone: 720-754-4800
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Abhinav P Deol
Phone: 313-576-8093
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Hackensack, New Jersey 07601
Principal Investigator: Scott Rowley
Phone: 201-336-8297
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
La Jolla, California 92093
Principal Investigator: Matthew Wieduwilt
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Gary Schiller
Phone: 310-825-5513
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Ian W. Flinn
Phone: 615-339-7274
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Sanjay Mohan
Phone: 615-936-8422
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Portland, Oregon 97227
Principal Investigator: Richard T. Maziarz
Phone: 503-494-7894
?
mi
from
Portland, OR
Click here to add this to my saved trials
216 South Kingshighway Boulevard
Saint Louis, Missouri 63110
Principal Investigator: Camille N. Abboud
Phone: 314-454-8323
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Jose Carlos Cruz
Phone: +1 210 575 6904
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Seattle, Washington 98109
Principal Investigator: Bart Scott
Phone: 206-667-1990
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Hugo Fernandez
Phone: 813-745-6012
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Toronto, Ontario
?
mi
from
Toronto,
Click here to add this to my saved trials